Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Temporal association as a prerequisite factor of valsartan-induced lithium toxicity.

Lazarczyk MJ, Giannakopoulos P.

Bipolar Disord. 2014 Sep;16(6):662-6. doi: 10.1111/bdi.12174. Epub 2013 Dec 23.

PMID:
24372930
2.

Lithium intoxication after valsartan treatment.

Su YP, Chang CJ, Hwang TJ.

Psychiatry Clin Neurosci. 2007 Apr;61(2):204. No abstract available.

3.
4.

Valsartan in chronic heart failure.

Ripley TL.

Ann Pharmacother. 2005 Mar;39(3):460-9. Epub 2005 Feb 1. Review.

PMID:
15687480
5.

Potential drug interaction between lithium and valsartan.

Leung M, Remick RA.

J Clin Psychopharmacol. 2000 Jun;20(3):392-3. No abstract available.

PMID:
10831034
6.

Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study.

Wilting I, Heerdink ER, Mersch PP, den Boer JA, Egberts AC, Nolen WA.

Bipolar Disord. 2009 Jun;11(4):434-40. doi: 10.1111/j.1399-5618.2009.00699.x.

PMID:
19500096
7.

Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review.

Kalra A, Cooley C, Palaniswamy C, Kalra A, Zanotti-Cavazzoni SL.

Am J Ther. 2012 Nov;19(6):e189-92. doi: 10.1097/MJT.0b013e3181f28f84. Review.

PMID:
20838200
8.

Exanthematous drug eruption due to valsartan.

Ozturk G, Turk BG, Senturk B, Turkmen M, Kandiloglu G.

Cutan Ocul Toxicol. 2012 Dec;31(4):335-7. doi: 10.3109/15569527.2011.647179. Epub 2012 Jan 18.

PMID:
22257082
9.

A drug safety evaluation of valsartan.

Fogari R, Zoppi A.

Expert Opin Drug Saf. 2011 Mar;10(2):295-303. doi: 10.1517/14740338.2011.543416. Epub 2010 Dec 11. Review.

PMID:
21142805
10.

Parkinsonism and severe hypothyroidism in an elderly patient: a case of lithium toxicity due to pharmacological interactions.

Basile G, Epifanio A, Mandraffino R, Trifirò G.

J Clin Pharm Ther. 2014 Aug;39(4):452-4. doi: 10.1111/jcpt.12162. Epub 2014 Apr 12.

PMID:
24725285
11.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
12.

Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.

Bos-Thompson MA, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P, Morin D.

Ann Pharmacother. 2005 Jan;39(1):157-61. Epub 2004 Dec 8. Review. Erratum in: Ann Pharmacother. 2005 Feb;39(2):389.

PMID:
15590878
13.
14.
15.

Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake.

Weir MR, Smith DH, Neutel JM, Bedigian MP.

Am J Hypertens. 2001 Jul;14(7 Pt 1):665-71.

PMID:
11465651
16.

The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.

J Am Coll Cardiol. 2006 Feb 21;47(4):726-33. Epub 2006 Jan 26.

17.
18.

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.

19.
20.

[Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].

Roger N, Popovic I, Madelenat P, Mahieu-Caputo D.

Gynecol Obstet Fertil. 2007 Jun;35(6):556-60. Epub 2007 Jun 1. French.

PMID:
17544313

Supplemental Content

Support Center